Leave a Comment

Please enter your name.
Please enter a comment.

Trending
Zolgensma
Why didn’t nonprofits and the NIH require ‘reasonable’ pricing…
Why didn’t nonprofits and the NIH require ‘reasonable’ pricing for Zolgensma? That may happen in France
Apple health watch
Beware the hype over the Apple Watch heart app.…
Beware the hype over the Apple Watch heart app. The device could do more harm than…
Herpes viruses
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Recommended
23andme
Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing
Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing
Pharmalittle: Five companies offer $50 billion deal to settle…
Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of…
Sean Parker
Sean Parker, billionaire and philanthropist, gets an immunotherapy company…
Sean Parker, billionaire and philanthropist, gets an immunotherapy company off the ground

Recommended Stories

Sean Parker
Biotech

Sean Parker, billionaire and philanthropist, gets an immunotherapy company off the ground

By Adam Feuerstein

Alexion Pharmaceuticals Inc
Biotech

Alexion acquiring Achillion to expand reach into rare, immune-related disease

By Adam Feuerstein

DNA Strand - Abstract
Biotech

Blueprint and Ipsen to work together on treatment for ultra-rare genetic disorder

By Jonathan Saltzman — Boston Globe

Peanuts on red background
Biotech

FDA advisory panel recommends approval of Aimmune peanut allergy therapy

By Adam Feuerstein

Test tubes and pipette
Biotech

UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus

By Jonathan Saltzman — Boston Globe

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy